Ashley Dombkowski is the founder of Alladapt Immunotherapeutics. Alladapt Immunotherapeutics has raised $179M in total funding. Latest round: Series C.
Ashley Dombkowski is the Co-founder and CEO of Alladapt Immunotherapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for IgE-mediated food allergies. Prior to Alladapt, she was CEO and President of Cellics Therapeutics, where she raised significant funding and advanced a therapeutic candidate through clinical trials.
Full founder directory · Investor directory · Company funding database · Fundraising library